Stay updated with breaking news from Meets Primary Endpoint. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.
PRINCETON, N.J.--(BUSINESS WIRE)--Mar 28, 2024--
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally...
-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line...
/PRNewswire/ -- Legacy Healthcare, a clinical-stage biopharmaceutical company today announced positive results from the RAAINBOW phase 2/3 randomized...